AWY0.F Percheron Therapeutics Limited
- Market cap
- EUR 991K
- P/E
- -
- P/B
- 0.21x
- ROE
- -63.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is AWY0.F undervalued?
Graham numberThe Graham number of Percheron Therapeutics Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Percheron Therapeutics Limited fundamental analysis
No fundamental analysis for Percheron Therapeutics Limited yet.
Percheron Therapeutics Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in …
Full company profilePercheron Therapeutics Limited financial statements
Percheron Therapeutics Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating Income | -7.61M | -13.3M | -14.9M | -16.7M | -5.62M |
| EBITDA | - | -11.3M | -11.8M | -14.8M | -4.56M |
| Net Income | -5.81M | -11.4M | -11.9M | -14.9M | -4.79M |
| EPS | -0.01 | -0.02 | -0.01 | -0.01 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 22.4M | 12.8M | 14.5M | 12.4M | 8.22M |
| Total Liabilities | 1.30M | 2.87M | 5.17M | 2.43M | 692K |
| Shareholders' Equity | 21.1M | 9.98M | 9.36M | 10.0M | 7.53M |
| Cash & Short-term Investments | 19.2M | 11.0M | 11.9M | 10.2M | 4.05M |
| Cash Flow | |||||
| Capital Expenditure | 3.91K | 29.3K | 3.61K | 7.24K | 3.09M |
| Free Cash Flow | -7.81M | -8.18M | -10.1M | -15.7M | -8.05M |
| Ratios | |||||
| ROE | -27.5% | -114.1% | -127.3% | -149.2% | -63.6% |
| ROA | -25.9% | -88.6% | -82.0% | -120.0% | -58.3% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Percheron Therapeutics Limited dividends
Percheron Therapeutics Limited has not paid dividends in the last 5 fiscal years.
Who owns Percheron Therapeutics Limited
- Insiders 24.51%
- Institutions 0.00%
- Public & others 75.49%
- Shares outstanding 1.98B
- Free float 1.18B
Percheron Therapeutics Limited company profile
- Company name
- Percheron Therapeutics Limited
- Ticker
- AWY0.F
- ISIN
- AU0000317281
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- June
- Address
- Collins Place, Melbourne, VIC, Australia, 3000
- Phone
- 61 3 9827 8999
- Website
- percherontx.com
About Percheron Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of antisense pharmaceuticals for cancer and rare diseases in Australia. Its products pipeline includes HMBD-002, a recombinant humanised monoclonal IgG4 antibody, which completed phase I clinical trial to treat to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Percheron Therapeutics Limited management
4- Ms. Deborah Ambrosini B.Com., F.C.A.Company Secretary & CFO · born 1974
- Dr. Michael BakerCEO, MD & Director
- Ms. Valentina Dubljevic BSc, GAICD, MBBChief Technology Officer
- Dr. Eugene P. Kennedy F.A.C.S., M.D.Chief Medical Officer · born 1969